It's only worth what someone will pay for it. In this case, that price was $4.34 mil USD as negotiated by PWC to be paid by someone that used to work for PWC...lol. The unsealed Appendix C confirms the selling price & what was covered under the APA.
$BIOAQ I feel for you but the fact is: All 3 entities, all major assets including the plant, patents, r&d, etc sold for $4.3M usd - it's in clear black & white print right from the horses mouth in the 6th & 7th publicly posted PWC reports - PriceWaterhouseCoopers - PWC / Court appointed controller & insolvency/bankruptcy trustee. Whether you want to accept it or not, it's a done deal, legally signed, court approved in Cdn and the USA & posted publicly. There are a lot of things that would have to happen well ahead of time for a R/M to even be remotely considered, they have not happened, filings have not been submitted, filings will not be submitted, PWC controls "what's left" of BioAmber - they WILL not file anything & a R/M is not an option. Today's (Oct 26th) court date is to get approval for the stay till Dec 2018' so the rest of the minor assets that weren't part of Vioslis/LCY can be sold off and the company can be wound down to dissolution - FACT.